What you should know:
1. The merger also included a funding round that raised $22 million.
2. The company is advancing two therapies: larazotide, a therapy for celiac disease currently in a phase 3 trial, and GLP-1, which treats short bowel syndrome.
3. John Temperato will lead a management team that has brought a combined 15 drugs to market.
More articles on surgery centers:
Life after ramp-up: How COVID-19 will change ASCs forever
3 ASC nurses join COVID-19 front lines in New York
4 hospitals, health systems opening ASCs
